All In Biotech

Drug Trial Radar · NCT06614907

A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

A Randomized, Double-blinded, Parallel, Single-dose, PhaseⅠComparative Study to Evaluate the Pharmacokinetics and Safety of QL2108 to Dupixent® in Healthy Chinese Adult Subjects

Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 198 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

198

Actual

Start

Aug 31, 2024

Primary completion

Nov 15, 2024

Study completion Dec 27, 2024

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

It is a randomized, double-blinded, parallel, single-dose, PhaseⅠcomparative study to evaluate the pharmacokinetics and safety of QL2108 to Dupixent® in healthy Chinese adult subjects. A total of 198 healthy subjects are planned to be included and randomized at a ratio of 1:1 to receive single 300mg/2.0ml QL2108 injection or Dupixent®.

Conditions

  • Atopic Dermatitis

Interventions

  • QL2108 injectionDrug

    300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection

  • Dupixent®Drug

    300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics EndpointTime frame: 0-8weeks
  2. Pharmacokinetics EndpointTime frame: 0-8weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jinan Central Hospital

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.